Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of “Hold” from Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given an average recommendation of “Hold” by the twenty-three research firms that are currently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation, ten have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $20.8542.

NTLA has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Friday, July 17th. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 15th. The Goldman Sachs Group upped their price objective on Intellia Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a research note on Tuesday, April 28th. Wolfe Research lowered Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price objective for the company. in a report on Wednesday, July 15th. Finally, Wedbush raised their target price on Intellia Therapeutics from $12.00 to $17.00 and gave the stock a “neutral” rating in a research report on Friday, July 10th.

Insider Activity

In other Intellia Therapeutics news, EVP Edward J. Dulac III sold 4,677 shares of the firm’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total value of $84,186.00. Following the completion of the transaction, the executive vice president directly owned 156,286 shares of the company’s stock, valued at $2,813,148. This trade represents a 2.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Michael P. Dube sold 2,641 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the completion of the transaction, the chief accounting officer owned 66,886 shares of the company’s stock, valued at $1,122,347.08. This trade represents a 3.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Intellia Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of NTLA. BlackRock Inc. purchased a new stake in shares of Intellia Therapeutics during the second quarter valued at approximately $260,721,000. ARK Investment Management LLC increased its stake in shares of Intellia Therapeutics by 19.2% in the fourth quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock worth $127,724,000 after buying an additional 2,288,146 shares during the period. Vanguard Group Inc. raised its holdings in Intellia Therapeutics by 17.8% during the 4th quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock valued at $116,960,000 after buying an additional 1,965,181 shares during the last quarter. State Street Corp raised its holdings in Intellia Therapeutics by 29.1% during the 4th quarter. State Street Corp now owns 6,418,836 shares of the company’s stock valued at $57,705,000 after buying an additional 1,447,967 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in Intellia Therapeutics during the 1st quarter valued at $17,913,000. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA opened at $11.94 on Monday. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -3.55 and a beta of 1.81. Intellia Therapeutics has a fifty-two week low of $7.95 and a fifty-two week high of $28.25. The firm’s 50-day simple moving average is $13.65 and its 200 day simple moving average is $13.48.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.80). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.The company had revenue of $7.66 million for the quarter, compared to analysts’ expectations of $12.98 million. During the same quarter in the previous year, the firm earned ($0.98) earnings per share. Intellia Therapeutics’s quarterly revenue was down 46.4% on a year-over-year basis. On average, sell-side analysts predict that Intellia Therapeutics will post -3.18 EPS for the current year.

Intellia Therapeutics News Summary

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Evercore ISI upgraded Intellia Therapeutics, citing its “nex-z hypothesis.” The upgrade suggests the firm sees potential for the program to create meaningful long-term value and improve the company’s outlook. Intellia upgraded at Evercore ISI on nex-z hypothesis
• Positive Sentiment: Brookline Capital Markets modestly improved its fourth-quarter 2026 EPS forecast to a loss of $0.41 from a loss of $0.47. Its longer-term model still projects a return to profitability beginning in 2027, which may support the investment case if clinical development succeeds. Brookline Capital Markets estimates
• Neutral Sentiment: Bank of America Securities maintained a Hold rating, indicating that it does not currently see a strong enough catalyst to recommend buying or selling the shares. Bank of America Securities remains a Hold on Intellia Therapeutics
• Neutral Sentiment: Recent analysis highlighted narrowing losses but continued heavy research-and-development spending. Intellia’s latest quarterly revenue also trailed estimates, underscoring that the company remains dependent on clinical progress rather than current operating revenue. Will Intellia’s narrowing losses and heavy R&D spend shift its risk reward narrative?
• Negative Sentiment: Brookline reduced its EPS forecasts for the second and third quarters of 2026 and lowered the full-year estimate to a $2.84 loss from a $2.76 loss. More significantly, it sharply cut projected earnings for 2027–2030, signaling substantially lower expectations for Intellia’s eventual commercial opportunity.
• Negative Sentiment: Wall Street Zen downgraded NTLA to Strong Sell. Together with the lower long-term estimates and BofA’s Hold rating, the call reflects substantial uncertainty around clinical execution, cash usage and the timing of profitability. Intellia lowered to Strong Sell rating

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.